T. Wilson’s scientific contributions

Since years gestagenes are established as a therapy option in the treatment of endometriosis. Dienogest, propagated as a "new gestagen" from the 19-nortestosteron family, has some special characteristics. DNG has also interesting antiandrogenic effects and a favourable pharmacokinetic. Soon after its discovery in 1979, Dienogest was considered an effective endocrinological therapeutic option because of its strong effects on the human endometrium. Several DNG-studies with established GnRH-analoges did show a comparable efficacy on the study end-point "pain" but less side effects. DNG was introduced to the European market in 2009 as Visanne© with 2 mg/d. Together with GnRH analoga, the available gestagenes and the combined oral contraceptives, Dienogest is an additional effective substance for the endocrinological treatment of the chronic disease endometriosis. Despite DNG seems to offer an effective long-term therapy option for patients with acceptable quality of life, we should keep in mind that DNG is not the end of our efforts to discover innovative approaches in cause and treatment of endometriosis.